Zschäbitz S, Niegisch G
Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Deutschland.
Klinik für Urologie, Medizinische Fakultät, Heinrich-Heine-Universität, Düsseldorf, Deutschland.
Urologe A. 2020 Jul;59(7):804-809. doi: 10.1007/s00120-020-01236-3.
The approval of the PD‑1 and PD-L1 (programmed cell death [ligand] 1) antibodies pembrolizumab, nivolumab, and atezolizumab has fundamentally changed the therapeutic landscape of locally advanced or metastatic urothelial carcinoma. Checkpoint inhibitors (CPI) are the standard of care in second-line treatment if not already used in first line. They replace conventional chemotherapeutics such as vinflunine, paclitaxel, or docetaxel and offer a superior toxicity profile. This article provides an overview of current second-line treatment strategies for locally advanced or metastatic urothelial carcinoma.
程序性死亡蛋白1（PD-1）和程序性死亡配体1（PD-L1）抗体帕博利珠单抗、纳武利尤单抗和阿替利珠单抗的获批，从根本上改变了局部晚期或转移性尿路上皮癌的治疗格局。如果一线未使用过，检查点抑制剂（CPI）是二线治疗的标准方案。它们取代了传统化疗药物，如长春氟宁、紫杉醇或多西他赛，且毒性更低。本文概述了局部晚期或转移性尿路上皮癌目前的二线治疗策略。
